Faber L M, van Agthoven M, Uyl-de Groot C A, Löwenberg B, Huijgens P C
Academisch Ziekenhuis Vrije Universiteit, afd. Hematologie, Amsterdam.
Ned Tijdschr Geneeskd. 2000 Jun 17;144(25):1223-7.
To investigate current guidelines for diagnosis and treatment of intermediate or high grade non-Hodgkin's lymphoma (NHL), stage I-IV (Burkitt's and lymphoblastic lymphoma excluded) and to compare this with current clinical practice.
Descriptive.
An inventory of guidelines for diagnosis and treatment of NHL of the Regional Cancer Centres (RCCs) was made in mid-1998, an enquiry containing questions about the practical situation concerning the diagnosis and treatment of NHL patients was sent to 59 internists-haematologists in non-university hospitals of the RCC regions Amsterdam, Rotterdam and South.
Apart from the standard diagnostics, the RCCs recommended several examinations for staging. For the initial staging the haematologists not always requested the recommended CTs of chest and abdomen and most of them did no restaging after the last course of chemotherapy. Half of them left the assessment of lymph node biopsy samples to a lymphoma panel. The recommended primary treatment consisted mainly of chemotherapy with cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP). In certain regions, the schedule was slightly changed, with additional tenoposide and bleomycin (CHVmP/BV). The treatment schedules were heterogeneous, especially for stage I NHL. In leukopenia and/or thrombocytopenia, postponement was recommended, but dosage reduction was carried out immediately, especially in older patients, sometimes with administration of a haemopoietic growth factor. Recurrence NHL was treated in accordance with the guidelines with second-line chemotherapy, if possible followed by peripheral stem cell transplantation in a haematooncological centre.
Considering these results development of national guidelines for NHL would seem to be desirable.
研究针对Ⅰ-Ⅳ期(不包括伯基特淋巴瘤和淋巴母细胞淋巴瘤)中高级别非霍奇金淋巴瘤(NHL)的现行诊断和治疗指南,并将其与当前临床实践进行比较。
描述性研究。
1998年年中对各区域癌症中心(RCC)的NHL诊断和治疗指南进行了汇总,并向阿姆斯特丹、鹿特丹和南部RCC地区非大学医院的59名内科血液学家发送了一份调查问卷,其中包含有关NHL患者诊断和治疗实际情况的问题。
除了标准诊断外,RCC还推荐了几种分期检查。对于初始分期,血液学家并非总是要求进行推荐的胸部和腹部CT检查,而且大多数人在最后一个化疗疗程后没有进行再分期。其中一半人将淋巴结活检样本的评估交给了淋巴瘤专家小组。推荐的主要初始治疗方法主要是采用环磷酰胺-阿霉素-长春新碱-泼尼松(CHOP)化疗。在某些地区,方案略有改变,增加了依托泊苷和博来霉素(CHVmP/BV)。治疗方案各不相同,尤其是Ⅰ期NHL。对于白细胞减少和/或血小板减少,建议推迟治疗,但要立即减少剂量,尤其是老年患者,有时还会给予造血生长因子。复发性NHL按照指南采用二线化疗进行治疗,如有可能,随后在血液肿瘤中心进行外周干细胞移植。
考虑到这些结果,制定NHL的国家指南似乎是可取的。